Haemonetics Corporation (HAE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$52.64
Price Target
$84.60
Target Range
$70.00 — $94.00
Analyst Rating
Buy
Forward P/E10.6x
Trailing P/E15.9x
Forward PEG0.61
Implied Growth+32.4%
Median Target$88.00
Analyst Spread28.4%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$70
+33.0%
Consensus
$85
+60.7%
Bull Case
$94
+78.6%
HAE Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Haemonetics Corporation (HAE) has a Wall Street consensus price target of $84.60, based on estimates from 20 covering analysts. With the stock currently trading at $52.64, this represents a potential upside of +60.7%. The company has a market capitalization of $2.45B.
Analyst price targets range from a low of $70.00 to a high of $94.00, representing a 28% spread in expectations. The median target of $88.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HAE trades at a trailing P/E of 15.9x and forward P/E of 10.6x. The forward PEG ratio of 0.61 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +32.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+121.2%
Avg Forward P/E63.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TFXTeleflex Incorporated | $5.5B | $123.23 | $132.20 | +7.3% | Buy | 18.3x | 29 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 ITGRInteger Holdings Corporation | $3.0B | $86.29 | $98.00 | +13.6% | Buy | 13.3x | 14 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 NNOXNano-X Imaging Ltd. | $117M | $1.79 | $18.00 | +905.6% | Buy | — | 5 |
 BAXBaxter International Inc. | $8.8B | $16.98 | $19.75 | +16.3% | Hold | 8.9x | 36 |
 BDXBecton, Dickinson and Company | $52.4B | $144.76 | $172.85 | +19.4% | Buy | 11.6x | 33 |
 ISRGIntuitive Surgical, Inc. | $160.4B | $451.73 | $622.60 | +37.8% | Buy | 43.7x | 55 |
 GMEDGlobus Medical, Inc. | $12.1B | $89.22 | $110.67 | +24.0% | Buy | 20.0x | 36 |
 ATRCAtriCure, Inc. | $1.4B | $28.01 | $50.67 | +80.9% | Buy | 373.5x | 19 |
Upside Potential Comparison
NNOXNVCRATRCISRGGMEDBDXBAXITGRSee HAE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HAE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HAE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
What is the HAE stock price target for 2026?
The consensus Wall Street price target for HAE is $84.6, representing 60.7% upside from the current price of $52.64. With 20 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is HAE a buy, sell, or hold?
HAE has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is mixed, with 10 Hold ratings making up the largest segment. The consensus 12-month price target of $84.6 implies 60.7% upside from current levels.
Is HAE stock overvalued or undervalued?
With a forward P/E of 10.6481x, HAE trades at a relatively low valuation. The consensus target of $84.6 implies 60.7% appreciation, suggesting meaningful undervaluation.
How high can HAE stock go?
The most bullish Wall Street analyst has a price target of $94 for HAE, while the most conservative target is $70. The consensus of $84.6 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover HAE stock?
HAE is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 10 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HAE stock forecast?
The 12-month HAE stock forecast based on 20 Wall Street analysts shows a consensus price target of $84.6, with estimates ranging from $70 (bear case) to $94 (bull case). The median consensus rating is "Buy".
What is HAE's forward P/E ratio?
HAE trades at a forward P/E ratio of 10.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 15.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy HAE stock?
Wall Street analysts are very optimistic on HAE, with a "Buy" consensus rating and $84.6 price target (60.7% upside). 10 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HAE price targets vary so much?
HAE analyst price targets range from $70 to $94, a 28% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $84.6 consensus represents the middle ground.